Adult: Initially, 200 mg once daily, may be titrated in increments of 200 mg at weekly intervals according to response and tolerability. Max: 600 mg once daily. Child: 6-11 years Initially, 100 mg once daily, may be titrated in increments of 100 mg at weekly intervals to the Max dose of 400 mg once daily according to response and tolerability; 12-17 years Initially, 200 mg once daily, may be increased to the Max dose of 400 mg once daily after 1 week according to response and tolerability.
Renal Impairment
eGFR (mL/min/1.73 m2)
Dosage
<30
Initially, 100 mg once daily, may be titrated in increments of 50-100 mg at weekly intervals according to response and tolerability. Max: 200 mg once daily.
Administration
Viloxazine May be taken with or without food. Swallow whole & do not chew/break/crush. Alternatively, may open the capsule and sprinkle the contents over a teaspoonful or tablespoonful of applesauce or pudding. Swallow the entire mixture without chewing within 15 minutes (for pudding) or 2 hours (for applesauce).
Contraindications
Concomitant use with or within 14 days after discontinuing MAOI therapy. Concomitant use with sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range.
Special Precautions
Patient with bipolar disorder, preexisting CV disease. Severe renal impairment (eGFR <30 mL/min/1.73 m2). Children. Pregnancy and lactation.
Adverse Reactions
Significant: Suicidal thoughts and behaviour, increased heart rate and diastolic blood pressure; may activate manic or mixed episode (in patients with bipolar disorder); somnolence, fatigue. Gastrointestinal disorders: Nausea, vomiting, constipation, dry mouth, abdominal pain, GERD. General disorders and administration site conditions: Pyrexia. Metabolism and nutrition disorders: Decreased appetite. Nervous system disorders: Dizziness, headache. Psychiatric disorders: Insomnia, irritability. Respiratory, thoracic and mediastinal disorders: URTI.
Patient Counseling Information
This drug may cause drowsiness and tiredness, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor heart rate and blood pressure (at baseline and periodically during treatment); liver enzymes, serum creatinine, GFR; weight (periodically). Screen for bipolar disorder (e.g. personal or family history of bipolar disorder, suicide, or depression) before initiating treatment. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviour during the 1st few months of therapy or during dose changes.
Drug Interactions
May significantly increase the total exposure (but not peak exposure) of CYP1A2 substrates (e.g. caffeine, theophylline, clozapine, pirfenidone), which may increase the risk of adverse reactions associated with these agents. May increase the exposure of CYP3A4 substrates (e.g. midazolam) and CYP2D6 substrates (e.g. dextromethorphan). Potentially Fatal: Concomitant use with MAOI may result in hypertensive crisis.
Food Interaction
May reduce absorption with high-fat meal (800-1,000 calories).
Action
Description: Overview: Viloxazine is a selective norepinephrine reuptake inhibitor. Mechanism of Action: The exact mechanism of action of viloxazine in treating attention deficit hyperactivity disorder is not fully understood; however, it is believed to bind to norepinephrine transporter and inhibit norepinephrine reuptake. Additionally, it binds to and exhibits partial agonist effect at 5-HT2C receptor. Pharmacodynamics: Viloxazine has no effect on PR interval or QRS duration, and it does not cause clinically relevant QT interval prolongation even at doses up to 3 times the Max recommended dose. However, nonclinical studies indicate that viloxazine may inhibit cardiac sodium channels. Pharmacokinetics: Absorption: High-fat meal (800-1,000 calories) may decrease absorption. Bioavailability: Approx 88%. Time to peak plasma concentration: Approx 5 hours (range: 3-9 hours). Distribution: Enters breast milk. Plasma protein binding: 76-82%. Metabolism: Metabolised mainly by CYP2D6, UGT1A9, and UGT2B15 to the major metabolite, 5-hydroxy-viloxazine glucuronide. Excretion: Mainly via urine (90%); faeces (<1%). Elimination half-life: 7.02 hours.
Chemical Structure
Viloxazine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5666, Viloxazine. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed Nov. 25, 2025.
N06AX09 - viloxazine ; Belongs to the class of other antidepressants.
References
Brayfield A, Cadart C (eds). Viloxazine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/10/2025.Qelbree Capsule, Extended Release (Supernus Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 15/10/2025.Viloxazine Hydrochloride. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 15/10/2025.Viloxazine. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 15/10/2025.
Sign Out
Continue with Google